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Abstract
The hormone corticotropin (ACTH) is employed as therapy for diverse neurological disorders, but
the mechanisms for its efficacy remain unknown. ACTH promotes the release of adrenal steroids
(glucocorticoids), and most ACTH effects on the central nervous system (CNS) have been attributed
to activation of glucocorticoid receptors. However, in several human disorders, ACTH has
therapeutic actions that differ qualitatively or quantitatively from those of steroids. This study tested
the hypothesis that ACTH directly influences limbic neurons via the recently characterized
melanocortin receptors and focused on the effects of ACTH on the expression of corticotropin-
releasing hormone (CRH), a neuropeptide involved in neuroimmune functions and in certain
developmental seizures. The results demonstrated that ACTH potently reduced CRH expression in
amygdala neurons. This down-regulation was not abolished by experimental elimination of steroids
or by blocking their receptors and was reproduced by a centrally administered ACTH fragment that
does not promote steroid release. Importantly, selective blocking of melanocortin receptors prevented
ACTH-induced down-regulation of CRH expression. Taken together, these data indicate that ACTH
activates central melanocortin receptors to modulate CRH gene expression in amygdala, supporting
the notion that direct, steroid-independent actions of ACTH may account for some of its established
clinical effects on the CNS.
The hormone corticotropin (ACTH) has been used extensively to treat neurological disorders.
In some auto-immune disorders (eg, opsoclonus-myoclonus) and in certain developmental
seizure disorders (eg, infantile spasms), ACTH possesses increased efficacy or a different
spectrum of effects compared to adrenal steroids.1–4 However, the mechanisms for these
singular actions of ACTH on the central nervous system (CNS) have remained unresolved.1,
5
Native ACTH is synthesized in the pituitary and functions to stimulate the adrenal cortex to
release steroids into the blood stream as part of the neuroendocrine stress response. Neurons
containing ACTH have been localized to the CNS, particularly the hypothalamus, and ACTH-
immunoreactive cell bodies or fibers have also been described in amygdala, cerebral cortex,
brainstem, and cerebellum.6,7 In contrast to pituitary ACTH, the functions of CNS ACTH have
not been well-defined. Evidence from both human and animal studies has suggested that CNS
ACTH may function as a neurotransmitter/neuromodulator.1,8 Indeed, central physiological
roles for ACTH, including modulation of learning and memory processes and facilitation of
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arousal states, have been suggested, but the mechanisms for these actions of ACTH have
remained unclear.1,8 Characterization of the melanocortin receptor family, consisting of
several members possessing binding affinity for ACTH,9,10 has yielded insight regarding the
likely sites and mechanisms of ACTH effects. However, the downstream effects of activation
of these receptors and the specific molecular changes that can lead to the clinical effects of
ACTH on CNS function have not been elucidated.
Pituitary ACTH synthesis and secretion are regulated by the peptide corticotropin-releasing
hormone (CRH), and both hormones participate in the neuroendocrine response to stress.
Furthermore, ACTH reduces CRH gene expression in hypothalamus as part of the
neuroendocrine feedback loop of the stress response.11 ACTH and CRH are found in close
proximity in the amygdala, and complex interactions between the ACTH- and CRH-expressing
neuronal systems have been suggested:12–14 For example, ACTH-immunoreactive (ir) fibers
have been demonstrated in the amygdaloid central nucleus, a major limbic locus of CRH-
expressing neurons. Could regulation of CRH expression account for some of the actions of
ACTH on CNS function?
Indeed, down-regulation of CRH by ACTH provides an attractive mechanism for some of the
clinical effects of the latter. CRH has been implicated in neuroimmune functions,15–17 in
learning and memory,18,19 and in developmental seizures.20,21 In the clinical context, CRH
modulates immune function in a complex manner,15,22 and regulation of its actions may
mediate some of the efficacy of ACTH in autoimmune disorders. Importantly, ACTH is much
more potent than steroids in infantile spasms.3,4 Whereas the etiology of this disorder remains
entirely unclear, evidence from human23,24 and animal20,21 data supports a potential role of
stress-activated proconvulsant actions of CRH on limbic neurons. Thus, the all-or-none effects
of ACTH on these seizures may involve reduction of CRH availability at limbic synapses.21,
25
The goal of the current studies was to examine whether ACTH directly influenced CRH gene
expression in the immature rat amygdala. Because steroids also regulate CRH expression in
this region, this study focused on discerning steroid-independent effects, testing the hypothesis
that ACTH suppresses CRH expression in amygdaloid central nucleus (ACe) directly, via
activation of central melanocortin receptors.
Materials and Methods
Materials
ACTH (Acthargel; Rhone-Poulenc Rorer, Collegeville, PA) was administered into the
peritoneal cavity (i.p.) at a high dose (80 I.U./kg), because of the limited blood–brain barrier
penetration of the peptide.26,27 ACTH4–10, an analog that binds melanocortin receptors but
does not induce steroid secretion from the adrenal, was a gift from Dr. J. Rivier. ACTH4–10
was dissolved in 0.9% saline and infused into the cerebral ventricles (i.c.v.) in a dose of 1 μg.
RU 38486 (a gift from Roussel UCLAF, Romainville, France) was dissolved in 2% ethanol/
98% polyethelene-glycol and injected i.p. (100 mg/kg).28 SHU9119 (courtesy of Dr. K.
Yagaloff, Roche) was dissolved in 0.9% saline and infused i.c.v. (1 nmol).29
Experimental Design
Several experiments were carried out to test the hypothesis that ACTH alters CRH gene
expression in ACe independently of the effects of steroids. These experiments were performed
on developing rats (postnatal days 9–11) for several reasons: 1) ACTH is used frequently and
in large doses in human infants during a stage of brain development generally equivalent to
that of the immature rat in the second postnatal week.30 2) Previous work from our laboratory
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has characterized the levels and regulation of CRH mRNA expression in ACe during this age.
21,31 Experimental groups were chosen to manipulate independently levels of ACTH and of
circulating steroids (glucocorticoids). These groups and the respective hormonal profiles of
each are schematized in the Table.
Experimental Groups
1. Controls. Several control groups were used so that, for each experiment, controls
received vehicle or surgical procedure corresponding to that of the respective
experimental groups. Controls were sacrificed concurrently with other groups at 2–4
PM to minimize potential diurnal variation in CRH mRNA levels, in endogenous
plasma ACTH and steroids or in the sensitivity of CRH to regulation by ACTH or
steroids. All animals were sacrificed 4 hours after ACTH administration, a time that
has been found to be optimal, considering the half-life of CRH mRNA.28,31
2. ACTH i.p. recipients (n = 6) injected with ACTH and sacrificed 4 hours later. They
were compared with i.p. vehicle controls.
3. ACTH i.c.v. (n = 7). ACTH4–10 was infused (1 μl) via stainless steel cannulae
implanted into the lateral cerebral ventricle 24 hours prior to drug administration. This
ACTH analog was chosen because it binds to melanocortin receptors but does not
stimulate steroid secretion.
4. Adrenalectomy (n = 5). Animals underwent bilateral adrenalectomy 24 hours prior to
experiments. They were also injected i.p. or infused i.c.v. with vehicle and sacrificed
4 hours later.
5. Adrenalectomy + ACTH i.p. (n = 7 ). Animals subjected to bilateral adrenalectomy
were injected the following day with ACTH and sacrificed 4 hours later. (Controls
were sham- adrenalectomized and administered vehicle i.p.)
6. RU 38486 (n = 5). Animals were injected i.p. with the glucocorticoid receptor
antagonist RU 38486 and sacrificed 4 hours later.
7. RU 38486 + ACTH i.p. (n = 5). RU 38486 was injected to intact animals 35–40
minutes prior to administration of ACTH. Animals were sacrificed 4 hours after
ACTH injection.
8. Adrenalectomy and SHU9119 (n = 5). Animals underwent bilateral adrenalectomy,
resulting in elevated endogenous ACTH levels (because of elimination of endogenous
steroid feedback). To block the actions of this endogenous ACTH, the melanocortin
receptor-4 antagonist SHU9119 was infused i.c.v. on the following day, and animals
were sacrificed 4 hours later.
For obvious technical reasons, experiments were performed in “batches.” However, each
included both experimental animals and littermate controls, and tissue processing and data
analysis were performed to include all experiments.
Animals and Tissue Preparation
Offspring of timed-pregnancy Sprague Dawley-derived rats (Zivic-Miller, Zelienople, PA)
were used in this study. Dams were maintained in an NIH-approved facility on a 12 hour light/
dark cycle (lights on at 7 AM). Cages were monitored every 12 hours for the presence of pups,
and the date of birth was considered day 0; litters were culled within 24 hours of delivery to
12 pups. Rats were killed by decapitation, and brains were rapidly removed and frozen on dry
ice for subsequent in situ hybridization. Trunk blood was collected at the time of sacrifice for
measurement of plasma ACTH and corticosterone (the major glucocorticoid in rat) levels using
commercial radioimmunoassay (RIA) kits (Inc-star, Stillwater, MN, and ICN, Irvine, CA,
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respectively). All experiments were carried out according to NIH guidelines for the care of
experimental animals and were approved by the Institutional Animal Care Committee.
Adrenalectomy and Cannulae Implantation Surgery
Surgery was performed with the animals under halothane anesthesia 24 hours prior to
experiments, to permit adequate recovery from the procedure. To eliminate endogenous
steroids, bilateral adrenalectomy was performed via dorsal incisions. Sham adrenalectomy
consisted of opening the peritoneal cavity without removal of the adrenals. Incisions were
closed using acrylic glue (Krazy Glue; Elmer’s Products, Inc., Columbus, OH). The
completeness of adrenalectomy was verified by visual inspection as well as by hormonal
measurements: Animals with corticosterone levels >0.2 μg/dl were considered not fully
adrenalectomized and were eliminated from the study. For i.c.v. infusions, stainless steel
cannulae were implanted into the lateral cerebral ventricle using an infant-rat stereotaxic
apparatus (Kopf, Tujunga, CA) and stereotaxic coordinates (P 0.7 mm, L 2 mm, and V 3.3 mm
from bregma), as published elsewhere.32,33 When both adrenalectomy and cannula were
required, surgical procedures were performed sequentially, during a single anesthesia session.
In Situ Hybridization Histochemistry for CRH mRNA
In situ hybridization (ISH) histochemistry was performed as described previously.31 Briefly,
20 μm coronal sections were collected on gelatin-coated slides and stored at −80°C. Sections
were thawed, air dried, fixed in paraformaldehyde, dehydrated, and rehydrated through graded
ethanols, then exposed to 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8) and
dehydrated. Prehybridization and hybridization steps were performed at 40°C in a humidified
chamber. Following a 1 hour prehybridization, sections were hybridized overnight (20 hours)
with a deoxyoligonucleotide probe complementary to the coding region of CRH mRNA and
3′-end-labeled with 35S-dATP. Sections were then washed and apposed to film (Hyperfilm β-
Max; Amersham, Arlington Heights, IL) for 7–14 days. Selected sections were also dipped in
emulsion (NTB-2; Eastman Kodak, Rochester, NY) and exposed for 3 or 4 weeks.
Semiquantitative Analysis of CRH mRNA and Statistical Considerations
Semiquantitative analysis of CRH mRNA ISH signal was performed on digitized films using
the ImageTool software program (UTHSC, San Antonio, TX) as described elsewhere.31,34 For
balanced comparison among the different experimental groups, five anatomically matched
sections per region per brain were analyzed. Unbiased methods for section sampling have been
described in detail elsewhere,34 and all analyses were performed without knowledge of
treatment group (blindly). 14C standards were used to ascertain that analyzed signals fell in the
linear range, and values are expressed as relative optical density units (ROD). Differences
among groups were determined using a one-way analysis of variance (ANOVA) or Student’s
t test, as appropriate (Prism GraphPad, San Diego, CA), and significance levels were set at p
< 0.05. Further analysis used Tukey’s multiple comparison posthoc tests to determine the
source of the detected significance in the ANOVAs.
Results
Administration of Exogenous ACTH Down-Regulates CRH mRNA in ACe
CRH mRNA levels in ACe were significantly reduced by systemic administration of ACTH:
82 ± 4 and 53 ± 12 ROD in the control and ACTH groups, respectively (a 35% reduction; t =
2.67; df = 23; p < 0.02). Figure 1 shows CRH mRNA expression in representative
photomicrographs of coronal brain sections derived from both groups; Figure 2A depicts semi-
quantitative analyses of the intensity of the CRH mRNA signal.
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Glucocorticoid Receptor Activation Is Not Required for ACTH-Induced Down-Regulation of
CRH mRNA in ACe
ACTH, given systemically, led to a significant reduction in CRH mRNA expression in ACe
also in the absence of endogenous steroids (Fig 2A,C). Thus, in adrenalectomized rats—as in
intact littermates—ACTH resulted in a significant (33%) suppression of CRH mRNA levels
in ACe compared to vehicle-injected, sham-operated controls (56 ± 8 vs. 84 ± 4 ROD units,
respectively; t = 3.1; df = 18; p < 0.01), indicating that endogenous steroids were not required
for this effect. It should be noted that adrenalectomy—eliminating steroids and the consequent
negative feedback on ACTH secretion—resulted in high levels of intrinsic, endogenous ACTH
(Fig 2B). These ACTH levels, by themselves, were sufficient to down-regulate significantly
CRH mRNA in ACe (34% reduction from sham-operated controls; see Fig 2A,B; t = 2.3; df
= 18; p < 0.05). No further suppression of CRH expression resulted from adding exogenous
ACTH to these animals, indicating that the high endogenous ACTH levels after adrenalectomy
maximally activated melanocortin receptors, and further reduction of CRH expression was not
possible via this mechanism. Additional reduction of CRH mRNA levels required an
independent mechanism, i.e., blocking of the enhancing action of glucocorticoid receptor
activation (see below).
Adrenalectomy and ACTH Administration Determine Plasma ACTH and Steroid Levels
The expected changes in plasma stress hormones were observed after the experimental
interventions reported here (Fig 2B,C). ACTH levels were significantly elevated in animals
given exogenous ACTH (695 ± 50.7 pg/ml) and in adrenalectomized animals (296.3 ± 53.4
pg/ml) compared to controls (118.5 ± 16.37 pg/ml). In addition, additive effects of
administration of exogenous ACTH and adrenalectomy were apparent, leading to plasma
ACTH levels of 1475 ± 165.2 pg/ml, significantly higher than those of either treatment alone
[F(24) = 12; p < 0.0001, one-way ANOVA]. Plasma corticosterone levels increased
significantly after ACTH administration (6.8 ± 0.9 vs. 1.05 ± 0.19 μg/dl in controls), whereas
corticosterone levels in adrenalectomized animals were negligible [F(28) = 42.1; p < 0.0001,
one-way ANOVA].
ACTH Alters CRH mRNA Expression in ACe via a Central Effect
Similarly to systemically administered ACTH, the analog ACTH4–10 infused i.c.v. resulted in
a significant down-regulation of CRH mRNA expression in ACe [45% reduction from i.c.v.
vehicle-infused control levels (Fig 3); t = 4.04; p < 0.001]. The dose of ACTH4–10 used here
was relatively small and was therefore unlikely to reach the adrenal when given i.c.v. In
addition, this ACTH analog does not stimulate corticosterone secretion from the adrenal.1
Indeed, as shown in Figure 3, plasma corticosterone levels of ACTH4–10-infused rats were not
higher than those of vehicle-treated controls, whereas systemic ACTH led to a marked increase
in plasma corticosterone at the time of sacrifice (see Fig 2C). These data suggest that
ACTH4–10 (and ACTH) reduced CRH expression in ACe via a central rather than a steroid-
mediated peripheral mechanism.
ACTH Influences CRH mRNA Levels in ACe by Activating Melanocortin Receptors,
Independently of Glucocorticoid Receptor Occupancy
Further insight into the mechanism by which ACTH down-regulated CRH expression in ACe
was gained by administering the melanocortin receptor-4 blocker SHU9119 and the
glucocorticoid receptor antagonist RU 38486. As is evident from Figure 4A, in the setting of
high endogenous plasma ACTH levels achieved by adrenalectomy, administration of
SHU9119 blocked ACTH-induced reduction of CRH mRNA in ACe [90 ± 11 ROD in (SHU
+ Adx) vs. 55 ± 12 ROD in adrenalectomy alone]. In contrast, when RU 38486 was given to
intact animals, together with ACTH, it failed to block the effects of ACTH administration on
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CRH mRNA expression in ACe [30 ± 9 ROD in (ACTH + RU 38486), a 63% reduction from
i.p.-injected controls; t = 5.3; df = 8; p < 0.001; Fig 4B]. These data indicate that activation of
melanocortin receptors, but not of glucocorticoid receptors, is required for the actions of ACTH
on CRH expression in ACe.
Actions of ACTH on CRH Expression Are Region-Specific
The direct, steroid-independent down-regulation of CRH mRNA expression by ACTH was
specific to ACe. Analysis of ACTH and steroid plasma levels and the corresponding CRH
mRNA levels in hypothalamus and hippocampus (Fig 5) revealed distinct regional patterns:
In hypothalamic paraventricular nucleus (PVN), CRH mRNA levels correlated inversely with
plasma glucocorticoids, consistently with previous reports.35,36 ACTH administration,
inducing high plasma corticosterone levels, reduced CRH mRNA expression 40% in PVN (290
± 40 ROD in ACTH-treated vs. 480 ± 30 ROD in controls), whereas adrenalectomy, eliminating
plasma glucocorticoids, enhanced PVN CRH mRNA levels 108% [830 ± 150 ROD in
adrenalectomy vs. 400 ± 30 ROD in sham adrenalectomy controls; F(24) = 6.8; p < 0.01, one-
way ANOVA]. No consistent correlation of PVN CRH mRNA expression with plasma ACTH
levels was noted.
In hippocampus, exogenous ACTH did not alter CRH mRNA expression in any of the analyzed
fields (CA1, CA3, and dentate gyrus; Fig 5). Steroid elimination via adrenalectomy
significantly decreased CRH mRNA levels in CA1 neurons [F(25) = 10.44; p < 0.0001, one-
way ANOVA], known to express a high density of glucocorticoid receptors, but not in the
granule cell layer of the dentate gyrus.
Discussion
This study demonstrates direct actions of systemically or centrally administered ACTH on
limbic neurons that are independent of adrenal steroids. ACTH-induced reduction of CRH
expression in amygdala may provide a mechanism for the efficacy of ACTH in several human
disorders. Importantly, these effects of ACTH involve activation of specific melanocortin
receptors, which may provide new and important therapeutic targets.
ACTH has been used for treating a variety of neurological disorders. An established effect of
this hormone includes activation of adrenal steroid secretion, and the latter has generally been
considered as the major mechanism of action of ACTH. However, release of adrenal steroids
leading to activation of steroid receptors cannot fully explain the spectrum and magnitude of
the therapeutic effects of ACTH.
For example, both ACTH and steroids have been shown to be effective in treating certain
childhood seizures,37,38 particularly infantile spasms.3,20,39 However, for this disorder, ACTH
is a significantly more powerful agent than glucocorticoids.3,4 Indeed, both uncontrolled3 and
prospective, blinded, and controlled studies4 have shown that ACTH in very large doses is
significantly superior to large doses of steroids, controlling the seizures and normalizing the
EEG in 86–88% of individuals compared to 35–40%.3,4,39 It should be noted that the levels
of plasma steroids achieved after administration of the typical doses of prednisone should be
sufficient to saturate neuronal glucocorticoid receptors.40 In addition, most studies demonstrate
the superior efficacy of higher compared to relatively lower doses of ACTH3,4,41,42 (but see
Hrachovy et al43), although these “lower” doses suffice to stimulate maximally secretion of
steroids from the adrenal.
These clinical data raise several issues: First, if ACTH acts via steroids, then maximal doses
of both agents should have similar effects. Second, once doses of ACTH that suffice to release
endogenous steroids maximally are used, then higher doses should not have additional benefits.
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The enhanced potency of ACTH compared to steroids and the superiority of extremely high
doses of ACTH compared to lower one are consistent with direct, steroid-independent actions
of ACTH within the CNS. In addition, the poor penetration of systemically given ACTH
through the blood–brain barrier26,27 may underlie the requirement for large systemic doses.
The studies described here support the notion of direct CNS actions of ACTH. Using doses
analogous to those used clinically, we show that systemic ACTH influences gene expression
in specific brain regions regardless of the presence or absence of adrenal steroids. We further
show that these effects are generated by ACTH given either systemically or directly into the
cerebral ventricles. These effects persist when glucocorticoid receptors are blocked, but not
when a subtype of ACTH receptors (melanocortin receptors) is antagonized, showing that
activation of these latter receptors is required and sufficient for these actions of ACTH. These
findings are important for several reasons. First, they provide a mechanism for the direct actions
of ACTH on neurons, in both therapeutic and physiological contexts. In addition, they
demonstrate that ACTH may indeed be a native ligand for melanocortin receptor-4.
Melanocortin receptors, a family of transmembrane G-protein-coupled receptors, have been
demonstrated in regions subserving ACTH-mediated functions (eg, substantia nigra for
grooming and amygdala for learning and memory). In addition, activation of central
melanocortin receptors plays a role in appetitive and grooming behavior.10,44 However, several
endogenous members of the proopiomelanocortin family bind to melanocortin receptors, and
whether ACTH is an important endogenous ligand of these receptors has not been determined.
The current study demonstrates categorically that ACTH may activate melanocortin receptor-4.
Indeed, in adrenalectomized rats, the effect of increased endogenous ACTH on CRH
expression was abolished by administration of the melanocortin receptor-4 antagonist
SHU9119 directly into the CNS. These data strongly support the notion that endogenous ACTH
activates central melanocortin receptor-4 to influence CRH synthesis. Furthermore, the
receptor implicated here in the effects of ACTH on CRH gene expression, melanocortin
receptor-4, has been demonstrated in a number of brain regions, including hippocampus and
all three major divisions of the central amygdaloid nucleus.45 It is therefore interesting to note
that, unlike the hippocampus (expressing melanocortin receptors but devoid of endogenous
ACTH) and the hypothalamus (containing ACTH but lacking melanocortin receptor-4), ACe
is a site where both ACTH and melanocortin receptors coexist. Therefore, the current study is
consistent with a scenario in which ACTH, released from fiber terminals in ACe, acts locally
on melanocortin receptors located on CRH-expressing neurons. ACTH, given in clinical
settings should have similar effects.
Interestingly, the 4–10 fragment of ACTH that does not release adrenal steroids also led to the
depression of CRH gene expression. Earlier clinical studies have shown that shorter fragments,
such as ACTH4–9, that failed to release adrenal steroids were not efficacious in treating infantile
spasms.46,47 Currently available information explains the apparent discrepancy: New
information about the binding of ACTH fragments to melanocortin receptors shows that,
although the 4–10 fragment used here activates these receptors, the 4–9 fragment does not.
10,48 Thus, the current data are consistent with activation of melanocortin receptor as the
mechanism for the observed effects of ACTH on amygdala neurons.
Modulation of CRH synthesis may prove to be one of the mechanisms by which ACTH exerts
its profound and diverse effects on CNS function. For example, CRH has been shown to play
an important modulatory role in affective disorders49 and neuroimmune function.15,17,22
Cytokines including interleukins 1 and 2 up-regulate CRH expression in specific brain regions,
16,50 and these cytokines, in turn, are induced by stress, by mechanisms that may involve CRH
release.17 CRH released from central neurons interacts with immune responses both directly
and by activation of steroid release.17,22 In addition, a role for CRH as an excitatory
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neuromodulator that can provoke severe seizures early in life has been emerging.20,21,51 These
seizures originate in the amygdala and involve other limbic regions.51 A hypothesis for the
involvement of CRH in infantile spasms has been proposed20,21 and is supported by
abnormalities of the CRH-ACTH-steroid axis found in infants with this disorder.23,24 It has
been proposed that the myriad etiologies of infantile spasms share the characteristic of
activating the responses to stress, thus leading to enhanced CRH expression in the amygdala.
20,31 This leads to excessive neuronal excitability25,33 and seizures.21,51 By repressing CRH
expression, ACTH may decrease this hyperexcitability, ameliorating infantile spasms.20
Indeed, the time course and all-or-none effects of ACTH are consistent with such an effect.
20,39,43,52
In summary, the current study provides a potential mechanism for the efficacy of ACTH for
certain neuroimmune and developmental seizure disorders and highlights the ACTH-CRH
system as a potential target for development of new therapeutic agents.
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Differential regulation of CRH mRNA levels in ACe, hippocampus, and hypothalamic PVN
by ACTH and adrenal steroids. Photomicrographs of coronal brain sections subjected to ISH
for CRH mRNA. CRH mRNA expression in ACe (arrows, top row), PVN (arrows, second
row), and hippocampus (third row) are shown. ACTH treatment decreased CRH mRNA signal
over ACe. Adrenalectomy (ADX), by increasing endogenous ACTH levels, led to a similar
reduction of CRH gene expression in ACe (top row). In contrast to the ACe, ADX resulted in
up-regulation of CRH mRNA levels in PVN (middle row) and reduced CRH mRNA signal in
hippocampus (third row) compared to control sections. The bottom row depicts representative
darkfield photomicrographs of ACe (encircled region in left two panels) and PVN (right two
panels). A marked reduction in the number of CRH-expressing cells is evident in ACTH-treated
animals compared to controls. In PVN, increased CRH mRNA signal is visible in sections from
an ADX animal. Scale bar = 1,500 μm in top two rows, 90 μm in third row, 200 μm in bottom
row. Asterisks = basolateral nucleus; mpd, mpv = medial dorsal and medial ventral
parvicellular cell groups of PVN, respectively.
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Effects of ACTH on CRH mRNA levels in ACe. (A) Semiquantitative analysis of CRH mRNA
expression in ACe of immature rats subjected to selective hormone level manipulations. Signal
was analyzed over ACe following ISH as discussed in Materials and Methods. (B) CRH mRNA
levels in ACe correlated inversely with plasma ACTH. Thus, ACTH administration (ACTH
i.p.) or augmentation of endogenous ACTH (ADX) or both (ACTH i.p. + ADX) significantly
reduced CRH mRNA levels in ACe compared to both the i.p. vehicle-injected and the sham-
adrenalectomy, vehicle-injected control groups. No correlation between plasma corticosterone
levels and ACe-CRH mRNA was observed (C). *Significant difference from control and sham
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ADX; **significant difference from all other groups (p < 0.05). Values depict means ± SEM.
ADX = adrenalectomy.
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CRH mRNA expression in ACe is down-regulated by centrally administered ACTH analog
that is devoid of glucocorticoid secretion. Semiquantitative analysis (see Materials and
Methods) of CRH mRNA signal in sections of animals receiving an i.c.v. infusion of
ACTH4–10, an analog binding melanocortin receptors but not stimulating corticosterone (Cort).
Although infusion of ACTH4–10 did not induce Cort secretion (hatched bars, scale on right),
this analog reduced ACe-CRH mRNA levels significantly (solid bars, left scale). Values are
means ± SEM; *p < 0.05.
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Effects of ACTH on CRH mRNA expression in ACe require activation of MC4-Rs but not of
glucocorticoid receptors. (A) High endogenous plasma ACTH levels were achieved by ADX,
significantly reducing CRH mRNA levels (single asterisks). Administration of SHU9119,
however, abolished ACTH-induced reduction of CRH mRNA. (B) In contrast, coadministered
RU 38486 failed to block the effects of ACTH (i.p.) on CRH mRNA expression in ACe. In
fact, CRH mRNA levels in ACTH+ RU 38486 treated rats were significantly lower from those
given ACTH alone, as denoted by double asterisks. Values denote means ± SEM of values
achieved using semiquantitative analysis (see Materials and Methods). i.c.v. Controls and i.p.
controls received vehicle via the noted routes; ADX/icv were adrenalectomized and given i.c.v.
vehicle. Diamonds over the i.p. control and ACTH groups indicate that they correspond to
groups shown in Fig 2A.
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Differential regulation of CRH mRNA expression in hippocampal regions of immature rats by
glucocorticoids and ACTH. Semiquantitative analysis of signal over dentate gyrus (A), CA3
(B), and CA1 (C) was performed after ISH, as described in Materials and Methods. CRH
mRNA levels in CA1 (the region rich in steroid receptors in the immature rat) were reduced
by elimination of GCs (ADX), regardless of ACTH levels (C). CRH mRNA expression in other
hippocampal regions was not appreciably altered by these hormonal
manipulations.*Significant difference from i.p. vehicle-injected control and sham-ADX
animals given i.p. vehicle (p < 0.05). Values are means ± SEM. ADX = adrenalectomy.
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Table
Summary of Expected Plasma Hormone Levels
Experimental Groups ACTH Corticosterone
Control ↔ ↔
ACTH ↑ ↑
Adrenalectomy (ADX) ↑ ↓ ↓
ADX + ACTH ↑ ↑ ↓ ↓
Sham ADX ↔ ↔
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